top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
PRC1021
Prostate cancer tissue array, 102 cases of normal/benign (7 cases) and cancer (95 cases with grading and TNM staging data) tissues
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$363
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |
TNM Classification : Prostate carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
T1 - Clinically inapparant tumor not palpable or visible by imaging
T1a - Tumor incidental histologic findings in 5% or less of tissue resected
T1 b - Tumor incidental histologic findings in more than 5% of tissue resected
T1c - Tumor identified by needle biopsy
T2 - Tumor confined within the prostate
T2a - Tumor involves one lobe
T2b - Tumor involves two lobes
T3 - Tumor extends through the prostate capsule
T3a - Extracapsular extension
T3b - Tumor invades seminal vesicle
T4 - Tumor is fixed or invades adjacent structures other than seminal vesicle: (bladder neck, external sphincter, rectum, levator muscle and/or pelvic wall
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Regional lymph node metastasis
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
M1a - Non-regional lymph node(s)
M1b-Bone(s)
M1c-Other site(s)
Human
102
102
1.5mm
4um
8
13
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in prostate cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 74 | Prostate | Hyperplasia | |||
A02 | M | 68 | Prostate | Hyperplasia | |||
A03 | M | 64 | Prostate | Hyperplasia | |||
A04 | M | 43 | Prostate | Leiomyoma | |||
A05 | M | 34 | Prostate | Malignant schwannoma | |||
A06 | M | 60 | Prostate | Adenocarcinoma | II | T2N0M0 | |
A07 | M | 76 | Prostate | Hyperplasia | |||
A08 | M | 72 | Prostate | Adenocarcinoma | III | T2N0M0 | |
A09 | M | 63 | Prostate | Adenocarcinoma | II | T2N0M0 | |
A10 | M | 76 | Prostate | Adenocarcinoma | I | T2N0M0 | |
A11 | M | 82 | Prostate | Adenocarcinoma | III | T2N0M0 | |
A12 | M | 88 | Prostate | Adenocarcinoma | I | T2N0M0 | |
A13 | M | 77 | Prostate | Adenocarcinoma | II | T2N0M0 | |
B01 | M | 72 | Prostate | Adenocarcinoma | III | T2N0M0 | |
B02 | M | 78 | Prostate | Adenocarcinoma | III | T2N0M0 | |
B03 | M | 74 | Prostate | Adenocarcinoma | III | T3N0M0 | |
B04 | M | 69 | Prostate | Adenocarcinoma | II | T2N0M0 | |
B05 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
B06 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
B07 | M | 77 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
B08 | M | 77 | Prostate | Adenocarcinoma | II~III | T1N0M0 | |
B09 | M | 77 | Prostate | Adenocarcinoma | III | T2N0M0 | |
B10 | M | 62 | Prostate | Adenocarcinoma | I | T2N0M0 | |
B11 | M | 75 | Prostate | Adenocarcinoma | III | T2N0M0 | |
B12 | M | 67 | Prostate | Adenocarcinoma | II | T2N0M0 | |
B13 | M | 73 | Prostate | Adenocarcinoma | II | T2N0M0 | |
C01 | M | 74 | Prostate | Adenocarcinoma | I~II | T2N0M1 | |
C02 | M | 70 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C03 | M | 66 | Prostate | Adenocarcinoma | III | T1N0M0 | |
C04 | M | 75 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C05 | M | 59 | Prostate | Adenocarcinoma | I | T2N0M0 | |
C06 | M | 78 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C07 | M | 79 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C08 | M | 69 | Prostate | Adenocarcinoma | I | T1N0M0 | |
C09 | M | 51 | Prostate | Adenocarcinoma | II | T3N1M0 | |
C10 | M | 55 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C11 | M | 84 | Prostate | Adenocarcinoma | III | T1N0M0 | |
C12 | M | 73 | Prostate | Hyperplasia | |||
C13 | M | 54 | Prostate | Adenocarcinoma | II | T1N0M0 | |
D01 | M | 81 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D02 | M | 79 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D03 | M | 80 | Prostate | Adenocarcinoma | I | T2N0M0 | |
D04 | M | 77 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D05 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D06 | M | 68 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D07 | M | 78 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D08 | M | 87 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D09 | M | 70 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D10 | M | 77 | Prostate | Adenocarcinoma | I | T4N0M0 | |
D11 | M | 85 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D12 | M | 84 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D13 | M | 71 | Prostate | Adenocarcinoma | III | T2N0M0 | |
E01 | M | 73 | Prostate | Adenocarcinoma | III | T1N0M0 | |
E02 | M | 66 | Prostate | Adenocarcinoma | III | T2N0M0 | |
E03 | M | 72 | Prostate | Adenocarcinoma | I | T2N0M0 | |
E04 | M | 86 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E05 | M | 75 | Prostate | Adenocarcinoma | III | T2N0M0 | |
E06 | M | 75 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E07 | M | 80 | Prostate | Adenocarcinoma | III | T2N0M0 | |
E08 | M | 71 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E09 | M | 52 | Prostate | Adenocarcinoma | III | T2N0M0 | |
E10 | M | 73 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E11 | M | 73 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E12 | M | 76 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E13 | M | 67 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F01 | M | 76 | Prostate | Adenocarcinoma | II | T1N0M0 | |
F02 | M | 60 | Prostate | Adenocarcinoma | III | T2N0M0 | |
F03 | M | 74 | Prostate | Adenocarcinoma | I | T2N0M0 | |
F04 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
F05 | M | 83 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F06 | M | 91 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F07 | M | 67 | Prostate | Adenocarcinoma | I | T2N0M0 | |
F08 | M | 54 | Prostate | Adenocarcinoma | II | T1N0M0 | |
F09 | M | 68 | Prostate | Adenocarcinoma | I | T2N0M0 | |
F10 | M | 82 | Prostate | Adenocarcinoma | II | T1N0M0 | |
F11 | M | 59 | Prostate | Adenocarcinoma | II | T4N0M0 | |
F12 | M | 67 | Prostate | Adenocarcinoma | I | T2N0M0 | |
F13 | M | 86 | Prostate | Adenocarcinoma | III | T4N0M0 | |
G01 | M | 75 | Prostate | Adenocarcinoma | II | T2N0M0 | |
G02 | M | 75 | Prostate | Adenocarcinoma | II | T1N0M0 | |
G03 | M | 71 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G04 | M | 80 | Prostate | Adenocarcinoma | II | T2N0M0 | |
G05 | M | 71 | Prostate | Adenocarcinoma | III | T3N0M0 | |
G06 | M | 67 | Prostate | Adenocarcinoma | II | T2N0M0 | |
G07 | M | 64 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G08 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G09 | M | 71 | Prostate | Adenocarcinoma | III | T1N0M0 | |
G10 | M | 66 | Prostate | Adenocarcinoma | III | T4N0M0 | |
G11 | M | 42 | Prostate | Sarcomatoid carcinoma | IV | T2N0M0 | |
G12 | M | 87 | Prostate | Adenocarcinoma | III | T4N0M0 | |
H01 | M | 61 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H02 | M | 86 | Prostate | Adenocarcinoma | II | T2N0M0 | |
H03 | M | 80 | Prostate | Adenocarcinoma | I | T2N0M0 | |
H04 | M | 68 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H05 | M | 64 | Prostate | Adenocarcinoma | II | T4N1M0 | |
H06 | M | 78 | Prostate | Adenocarcinoma | II | T2N0M0 | |
H07 | M | 72 | Prostate | Adenocarcinoma | II | T2N0M0 | |
H08 | M | 75 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H09 | M | 80 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H10 | M | 77 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H11 | M | 69 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H12 | M | 60 | Prostate | Adenocarcinoma | I | T2N0M0 | |
null |
bottom of page